ArticleAdvanced biomedical research2025
Vaginal Royal Jelly for Vulvovaginal Candidiasis Treatment: A Randomized Clinical Trial.
Article in Advanced biomedical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vulvovaginal Candidiasis (VVC) is a prevalent and complex health issue in women. With the rising resistance to synthetic antifungal medications, there is a growing emphasis on exploring natural remedies that minimize disruption to the normal vaginal flora. The goal of this study is to evaluate the efficacy of vaginal Royal Jelly (RJ) compared with clotrimazole for VVC treatment. Materials and Methods: This single-blind randomized clinical trial was conducted from 2020 to 2022 at Iran University of Medical Sciences hospitals, involving a total of 90 patients diagnosed with vaginal candidiasis. Positive vaginal culture individuals were randomly allocated to receive either vaginal 1000 mg RJ soft gel capsules or (2%) Clotrimazole cream (45 participants per group). Clinical signs, symptoms, and laboratory tests were statistically compared at baseline and ten days post-treatment. The data were analyzed using the independent t-tests, Mann-Whitney, Chi-square, and Wilcoxon tests through SPSS version 22. Results: After 10 days of treatment, both groups demonstrated a significant decrease in Candida culture results ( Conclusions: The present study points out the therapeutic effects of vaginal RJ, a novel natural drug for improving VVC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.